

A photograph of two women and a baby. The woman in the foreground is wearing a blue patterned headscarf and a blue patterned top, smiling broadly. The woman behind her is wearing a green and white patterned headscarf and a green and white patterned top, also smiling. A baby is visible on the right side of the frame, looking towards the left. The background is a textured, greyish-blue surface.

SHARED VISION SHARED COMMITMENT

END~~HEP~~2030
The Hepatitis Fund

Toward a World Free of Viral Hepatitis
For Generations to Come

Activity Report
2019 - 2021

We gratefully acknowledge



for incubating the EndHep2030 project and
seed funding The Hepatitis Fund



With a limited lifespan to sunset in 2035, The Hepatitis Fund (a.k.a. “EndHep2030”) was conceived as a collective funding platform to mobilize public and private financial resources globally to accelerate action to eliminate viral hepatitis as a major public health threat, for a hepatitis-free world for generations to come.

The EndHep2030 project has been supported by:



and individual donors and volunteers



TrustLaw program



Contents

2. Foreword by the Co-Founders
3. About the Hepatitis Fund
5. The EndHep2030 Grants Programme
7. Current Grants Portfolio
9. The EndHep2030 M&E Framework
11. The Evolution of the EndHep2030 Project
13. Hepatitis by the Numbers

It takes concerted global efforts to tackle a major public health threat like viral hepatitis. I urge international health funding bodies and private foundations, large and small, to join The Hepatitis Fund by stepping out of their comfort zones with bold and decisive actions. Hepatitis can't wait.

Dr. SHIN Young-soo, director emeritus, WHO Western Pacific Region



Foreword

Ahead of the Curve. Stay the Course.

The World Hepatitis Summit (2 – 4 September 2015, Glasgow, Scotland) will go down in history as a note-worthy milestone in the global campaign to eliminate viral hepatitis as a major public health threat. It was during the summit that Wangsheng Li (then president of ZeShan Foundation) initiated a conversation with Dr. John Ward (then director of US CDC Division of Viral Hepatitis) and Dr. Shin Young-soo (then regional director for WHO Western Pacific region) to explore setting up an international funding mechanism to support efforts in hepatitis elimination, building on a tripartite partnership between the three organizations since 2009.

Fast-forwarding to summer 2019 while co-chairing the EndHep2030 initiative as a sponsored project of the Rockefeller Philanthropy Advisors (New York City), Wangsheng Li and Charles Gore (Founder of the World Hepatitis Alliance) began to set it in motion to transition the EndHep2030 project to be an independent grantmaking foundation dedicated to the elimination of viral hepatitis. Hence The Hepatitis Fund (aka “EndHep2030”), which remains the only hepatitis funding platform to date.

Having been incubating the EndHep2030 project since 2007, ZeShan Foundation, under the visionary leadership of its executive chair, the late Mrs. Laura Chen, became the seed funder for The Hepatitis Fund, while the Rockefeller Philanthropy Advisors provided start-up funding for the newly minted foundation. The rest is history.

As a young organization, little did we imagine we would be confronted by an unprecedented global pandemic like COVID-19.

Led by a small group of highly dedicated volunteer Board Directors, The Hepatitis Fund managed to stay the course through institutional development and organizational growth: establishing a robust governance structure and management system, and a grants programme underpinned by a strong M&E framework.

Finally, the EndHep2030 project would not have been where we are today if it had not been for a group of highly committed thought leaders and experts who served as advisors and/or committee members throughout the project’s formulation phases.



A handwritten signature in cursive script that reads "Wangsheng Li".

Wangsheng Li
Co-Founder



A handwritten signature in cursive script that reads "Charles Gore".

Charles Gore
Co-Founder

About The Hepatitis Fund

The Hepatitis Fund (aka “EndHep2030”) is a tax-exempt, grantmaking charity foundation registered in the Canton of Geneva, Switzerland. The Fund is under the supervision of the Swiss Federal Department of Interior.

The Hepatitis Fund is governed by an international Board of Directors, which sets the strategic directions and operational guidelines for the organization.

Co-Founders:

Wangsheng Li and Charles Gore

Board of Directors:

- ▶ Gregg Alton
- ▶ Manal El-Sayed
- ▶ Etienne Gard, board secretary and general counsel (till July 2020)
- ▶ Charles Gore, vice president and treasurer
- ▶ Gottfried Hirnschall
- ▶ Kenneth Kabagambe
- ▶ Wangsheng Li, founding president (till February 2021)
- ▶ Hwei Lynn Lau
- ▶ Carol Tissot, board secretary and general counsel

Official observer: Zeshan Foundation

The following governance documents are available for inspection upon request by concerned parties:

- ▶ Business Registration
- ▶ Exemption Letter
- ▶ Articles of Association
- ▶ Board Bylaws
- ▶ Policy on Conflict of Interest
- ▶ Policy on Safeguarding
- ▶ Policy on Grant Making
- ▶ Auditor’s Statement
- ▶ Statutory Financial Statement

Please send your request in writing to:
admin@endhep2030.org



The EndHep2030 Advisory Council

The scope of The Hepatitis Fund's activities spans many areas concerning hepatitis elimination, prevention of mother to child transmission, and care interventions.

Members of the Advisory Council have broad expertise in policy and advocacy, programmatic aspects of hepatitis prevention and care; they advise the Board and contribute to programmes with their diverse perspectives and expertise.

Joan Block

executive director (ret.), Hepatitis B Foundation

Saeed Hamid

co-chair, Coalition to Eradicate Viral Hepatitis in Asia Pacific

Homie Razavi

executive director, Center for Disease Analysis Foundation

Lewis Roberts

director, Gastroenterology and Hepatology Cancer Center at the Mayo Clinic

Shin Young-Soo

director emeritus, WHO Western Pacific Regional Office

Su Wang

president, World Hepatitis Alliance

ZeShan Foundation

Shared vision. Shared commitment

The EndHep2030 project is a product of collective commitment and dedication by many individuals who are recognized as thought leaders and experts in the hepatitis space. We gratefully acknowledge in particular the following for their contributions to the project over the years leading to the establishment of The Hepatitis Fund:



Melissa Berman, President and CEO
Rockefeller Philanthropy Advisors
as fiscal sponsor (November 2017 – October 2019)



David Ho (ADARC), Chair, High-Level
Roundtable on PMTCT. October 2010. Beijing,
China

Gottfried Hirnschall (WHO HQ) and **Ray Yip** (Gates Foundation),
Co-chairs, International Roundtable Summit on Funding for
Hepatitis Elimination. June 2016. Hong Kong SAR, China.



The EndHep2030 Grants Programme

Recognizing viral hepatitis as a major public health threat globally, The Hepatitis Fund strategically focuses on the Asia and Pacific and Sub-Saharan African regions while not losing sight of the rest of the world. This geographic emphasis guides our grants programme by focusing on the following three strategic areas:

1. Accelerating planning and implementation of national strategies

- ▶ Systems approach to achieving national elimination goals
- ▶ Decentralizing hepatitis services and task shifting of hepatitis care to the most effective level of care
- ▶ Strengthening hepatitis capacity at national and regional levels

2. Integrating hepatitis services delivery with Universal Health Coverage


- ▶ Elimination of mother to child transmission of hepatitis B by integrating with antenatal care
- ▶ Increase of birth dose of HBV vaccination coverage and inclusion of complete HBV vaccination in national immunization plans
- ▶ Enhance equity and service accessibility by rolling out cutting edge technologies

3. Strengthening public health response capability

- ▶ Establishing quality national data collection and modeling
- ▶ Improving existing data systems for better policy formulation and planning
- ▶ Integrating hepatitis with national sentinel network

The Hepatitis Fund's strategic investments demonstrate how best to introduce or augment interventions in low-income or under-resourced settings to overcome regional, national, or local barriers that hinder viral hepatitis response efforts so that we can save more lives more quickly.





The EndHep2030 Grants Programme was developed in the context of the roadmap for global elimination of viral hepatitis as articulated by the five pillars of the WHO Strategies for hepatitis elimination as a major public health threat.













Figure: The five strategic directions from WHO Global Health Sector Strategy 2016-2021

The Hepatitis Fund uniquely raises and directs funding to programs and initiatives that can achieve strong impact towards hepatitis elimination. The THF aims to provide the spark that stakeholders on the ground need to set transformative action in motion. This report contains key highlights of the catalytic work initiated in 2020, which will greatly improve the lives of those living with viral hepatitis.

Dr. Gottfried Hirnschall, director (ret.), WHO Department of HIV, Hepatitis, and STIs















Current Grant Portfolio

 Africa	 Africa/Zambia	 Americas/ Andes	 Asia/Pakistan	 Global
Grant Recipient: Center for Disease Analysis Foundation, Inc.	Grant Recipient: University Teaching Hospital (UTH-HAP)	Grant Recipient: Coalition for the Elimination of Hepatitis in the Andean region. PAHO-SAM-ORAS-CONHU	Grant Recipient: Association for Social Development ASD	Grant Recipient: Columbia University
Purpose: Support national data analytics to inform policy formulation, national planning and implementation in ten African countries	Purpose: Implement a decentralized and integrated strategy through a national capacity building training programme in Zambia which could become a model for the African continent	Purpose: Support a regional approach to hepatitis policy change in the Andean Region as a pilot for broader use in the Americas Region	Purpose: Demonstrate how to effectively increase hepatitis C screening and treatment by mobilizing rural health centres in high prevalence settings and then integrating hepatitis care into the regional healthcare systems	Purpose: Develop a monitoring and evaluation framework for viral hepatitis catalytic funding.
Expected outcomes: •10 African countries reached	Expected outcomes: •5 million people reached •30,000 people tested •2,000 people treated	Expected outcomes: •130.5 million people reached	Expected outcomes: •110 million people reached •40,000 people tested •2,000 people treated	Expected outcomes: •High quality monitoring and evaluation tool for all hepatitis related grants • Better understanding of progress towards hepatitis elimination
				
Areas of implementation	Areas of implementation	Areas of implementation	Areas of implementation	Areas of implementation
				
Grant US \$ 225,000	Grant US \$ 530,125	Grant US \$169,839	Grant US \$ 557,036	Grant US \$45,523

Acceleration * Integration * Task-shifting

Current Grant Portfolio

 Global <p>Grant Recipient: London School of Hygiene & Tropical Medicine</p> <p>Purpose: Expand public engagement in HBV/HCV and crowdsource to spur hepatitis policy</p> <p>Expected outcomes:</p> <ul style="list-style-type: none"> •Decreased stigma •Increased community engagement •Build local ownership of hepatitis programs  <p>Areas of implementation</p>  <p>Grant US \$ 250,000</p>	 Global <p>Grant Recipient: World Health Organization</p> <p>Purpose: Develop and demonstrate the WHO-One Health Tool for costing of national hepatitis responses, and for adoption in all member states.</p> <p>Expected outcomes:</p> <ul style="list-style-type: none"> •WHO Regional Advisors for hepatitis trained in four WHO regions. •5 countries reached •WHO-One Health Tool for standard for costing of national hepatitis responses developed to be used as the future standard for all countries <p>Areas of implementation</p>  <p>Grant US \$200,000</p>	 Global <p>Grant Recipient: World Hepatitis Alliance</p> <p>Purpose: Support efforts to maintain the momentum for a global campaign to eliminate viral hepatitis</p> <p>Expected outcomes:</p> <ul style="list-style-type: none"> • Global hepatitis community strengthened •Increased capacity for advocacy at the national, regional and global levels •Common acceptance that hepatitis elimination can be embedded in Universal Health Coverage post COVID-19 <p>Areas of implementation</p>  <p>Grant US \$ 32,970</p>	 Western Pacific/ Vietnam <p>Grant Recipient: PATH Vietnam</p> <p>Purpose: Demonstrate an integrated viral hepatitis strategy to increase access to diagnostic and treatment services in major urban areas with high prevalence in East Asia (HepLink).</p> <p>Expected outcomes:</p> <ul style="list-style-type: none"> • 41 million people reached • 20,000 people tested • 90% of people treated  <p>Areas of implementation</p>  <p>Grant US \$ 715,000</p>	 South-East Asia and Western Pacific <p>Grant Recipient: The Peter Doherty institute for Infection and Immunity</p> <p>Purpose: Develop and roll out an operational guide to assist countries in performing monitoring and evaluation in the WPRO and SEARO regions</p> <p>Expected outcomes:</p> <ul style="list-style-type: none"> • Increased capacity in the Asia Pacific Region to analyse the hepatitis landscape across countries • Augmented resources for advocacy • National planning, resource mobilization and allocation supported <p>Areas of implementation</p>  <p>Grant US \$225,000</p>
--	--	---	---	--

Funded areas key									
	Biomedical Prevention	Epidemiology	Screening and Testing	Human Resources	Other Prevention	Economics and Financing	Treatment and Cure	Policy and Advocacy	

The EndHep2030 M&E Framework

The catalytic impact of The Hepatitis Fund's philanthropic investment is measured through a comprehensive and cohesive monitoring and evaluation (M&E) framework, which reflects the five pillars of the WHO Strategies for Elimination of Viral Hepatitis and at the same time affords ample flexibility for funded projects to develop a tailored log-frame for implementation and evaluation.

The EndHep2030 M&E framework is not only a monitoring tool but also a platform for creating a community of learning and sharing for capacity building at national and local levels. It was designed with the lens to accelerate policy formulation and planning, enhance efficiency, and increase access to quality care by following the principles of systems approach. It provides the vocabulary necessary to articulate the catalytic impact of the funded projects.

The EndHep2030 M&E framework serves as an overarching rubric for evaluating the EndHep2030 grants programme as a whole and for tailoring thematic grants portfolios. It defines common denominators for assessing process, deliverables, and catalytic impact. It enables real-time learning and timely adjustment to mitigate the impact of force majeure events such as disruptions brought about by the Covid-19 global pandemic. Lessons

learned and information accumulated will be valuable contribution to the body of knowledge for the global campaign to eliminate viral hepatitis as a major public health threat.

The EndHep2030 M&E Framework is a work in progress. With input from our grantees and partners, and new insights from on-going operations research, the Framework will be further enhanced and put to practice by the broad hepatitis community globally.


HepLink is an exciting opportunity to initiate proactive community-based case detection and treatment of chronic hepatitis at the primary care level of the health system. Demonstrations of effective interventions that can accelerate attainment of this goal are essential to accelerating hepatitis elimination to reach SDG3

Klm Green, global program director, Primary Health Care, PATH



* Developed in partnership with the International Epidemiology and Global Health Services Delivery programme at Columbia University (New York City)

Framework for Catalytic Impact on Viral Hepatitis Elimination



Evolution of the EndHep2030 Project: A journey in catalytic philanthropy

The EndHep2030 project is the culminating result of a tripartite partnership dating back to 2008 between ZeShan Foundation, World Health Organization, and US Centers for Disease Control and Prevention.

The EndHep2030 project owes its existence to the late Mrs. Laura Chen, the then executive chair of ZeShan Foundation, who had the leadership vision of an international philanthropist to recognize hepatitis B as a major public health challenge that affects tens of millions of people throughout the world.

In 2015 the Member States of the United Nations adopted the 2030 Agenda for Sustainable Development providing "a shared blueprint for peace and prosperity for people and the planet, now and into the future." The agenda for the first time officially acknowledged hepatitis as a global health and development priority. The WHO Global Strategies for the Health Sector provided the road map for achieving the ambitious goals to eliminate viral hepatitis.

ZeShan Foundation was rightfully a trailblazer in urging its philanthropic peers to step up to the challenge of viral hepatitis. ZeShan started incubating the EndHep2030 project in its gestation phase by providing operating and staff support while providing millions in cash grants to various projects. With US CDC as a co-funding partner, ZeShan helped establish dedicated staff for hepatitis for WHO's Western Pacific Region with a decade-long commitment in funding.

It was during the first World Hepatitis Summit (September 2015, Glasgow, Scotland) that Wangsheng Li (then president of ZeShan Foundation) initiated a conversation with Dr. John Ward (then director of US CDC Division of Viral Hepatitis) and Dr. Shin Young-soo (then regional director for WHO Western Pacific region) to explore setting up an international funding mechanism to support efforts in hepatitis elimination.



To set the stage for rallying and mobilizing private philanthropy to invest in hepatitis elimination, ZeShan, WHO, and USCDC collaborated to organize the first International Roundtable Summit on Funding for Elimination of Viral Hepatitis (June 21 – 22 2016, Hong Kong SAR China). Thought leaders, leading hepatitis advocates, and public health officials from over 50 countries converged for this historic convening. A concrete action plan out of the summit was to address the yawning gap between the funding needs of the global campaign to eliminate viral hepatitis as a major public health threat and the lack luster response by the institutionalized philanthropy.

Hence EndHep2030, an international funding platform for philanthropic investment in the global campaign against viral hepatitis.




The Summit Organizing Committee

- Gottfried Hirnschall, WHO HQ
- Wangsheng Li, ZeShan Foundation
- Ying-Ru Lo, WHO WPRO
- Nicole Smith, US CDC
- John Ward, US CDC
- Stefan Wiktor, WHO HQ
- Summit Secretariat: Yan Chan and Nick Walsh

ZeShan is proud to have seeded The Hepatitis Fund, a capstone to our decade-long effort in helping the world move towards the goal of eliminating viral hepatitis. While ambitious, the goal is actually an achievable one, and it is this belief that had driven our late sister Laura, when she was leading our family foundation, to make a strategic commitment to this cause, including the incubation of The Hepatitis Fund, the only grant-making foundation of its kind dedicated to the global elimination of viral hepatitis as a major public health threat.

Wynnie and Annie Chen, Grants Committee Members, ZeShan Foundation

Hepatitis by the numbers: Global Burden of Diseases Compared*



Today, in the Asia-Pacific region, more people die from hepatitis than from HIV, TB, and malaria **combined.**



The hepatitis B virus is **50-100x** more infectious than HIV

Every year, 1,000,000 newborns are infected with hepatitis B- a resounding failure to preventing mother to child transmission despite the availability of the hepatitis B birth dose vaccine. These babies join the 360 million people living with viral hepatitis around the world and every 30 seconds, one of these people die. We have the tools for putting an end to the hepatitis B and C epidemics, but these interventions urgently need to be made available for everyone living with hepatitis. Hepatitis is one of the greatest global health tragedies, overlooked by international funders and development partners. Hepatitis Fund provides a much-needed funding vehicle to support and accelerate hepatitis elimination worldwide and save these lives. #HepCantWait



Dr. Su Wang, president, World Hepatitis Alliance

940,000
Annual mortality attributed to
HIV/AIDS

80%
of liver cancer cases
globally are caused by
viral hepatitis

1,000,000+
Number of newborns infected with
hepatitis B virus

1,450,000
Annual mortality attributed to
viral hepatitis

If no drastic actions are taken, by 2040, more people will be dying globally from hepatitis than from HIV, TB, and malaria combined.

Sources: WHO Global Hepatitis Report. 2017.
CDA Foundation Polaris Observatory 2018.

The need is great. The solutions are here. The time is **now** to end viral hepatitis.

EndHep2030's **catalytic funding** will be the spark that sets this historic effort in motion.

A number of barriers keep countries from properly addressing viral hepatitis. By funding highly effective activities to increase awareness of the problem and speed (or catalyze) prevention, diagnosis and treatment, EndHep2030 can help partners to overcome those barriers.

Our Goals:

Increase Awareness

Most people, including many policy makers, don't understand the severity of this world-wide epidemic nor know that measures exist now to prevent and treat hepatitis.

Raise and Disperse Catalytic Funding

Prioritize efforts and programs that will accelerate progress toward the elimination of viral hepatitis as a public health threat:

- Developing sustainable strategic plans at the national and sub-national level to guide effective program implementation.
- Optimizing human and financial resources within health budgets so funds are effectively used.
- Increasing availability of country-specific data that inform where and how to intervene most efficiently and effectively.
- Building health system capacity to deliver quality hepatitis prevention and treatment services.

Bring an End to Hepatitis as a Global Health Threat by 2030

EndHep2030's catalytic funding will be the impetus for this effort:

- Preventing childhood hepatitis B infections by improving vaccine delivery to newborns.
- Preventing new infections by promoting safer injection practices in healthcare settings and among people who inject drugs.
- Increasing the number of people diagnosed and linked to treatment through improved access to testing services.



Turning investment into **impact**.



The background of the entire image shows a group of people, primarily men, sitting around a large, round, light-colored wooden table. They are engaged in playing a board game, likely Go or a similar stone-based game. The men are dressed in casual attire, including jackets and a baseball cap. The scene is outdoors, with a blurred background suggesting a public space. The text is overlaid on this image.

END~~HEP~~2030 The Hepatitis Fund

**PHILANTHROPY AS A CATALYST IN THE GLOBAL CAMPAIGN TO
ELIMINATE VIRAL HEPATITIS AS A MAJOR PUBLIC HEALTH THREAT**

Join the fight.

**Be part of this
history-making endeavor.
EndHep2030.org**